GSK response to China investigation

15 July 2013

In response to the ongoing investigations by government authorities in China regarding our business in the country, GSK has issued the following statement:

We are deeply concerned and disappointed by these serious allegations of fraudulent behaviour and ethical misconduct by certain individuals at the company and third-party agencies. Such behaviour would be a clear breach of GSK's systems, governance procedures, values and standards. GSK has zero tolerance for any behaviour of this nature.

GSK shares the desire of the Chinese authorities to root out corruption. These allegations are shameful and we regret this has occurred.

We will cooperate fully with the Chinese authorities in the investigation of these new allegations. We will take all necessary action required by the outcome of this investigation.

In the meantime, we are taking a number of immediate actions. We are reviewing all third party agency relationships. We have put an immediate stop on the use of travel agencies that have been identified so far in this investigation and we are conducting a thorough review of all historic transactions related to travel agency use. We also intend to conduct a rigorous review of our compliance procedures in China.

GSK fully respects the laws and regulations in China and expects all staff to abide by them.

We also fully support the efforts of the Chinese authorities in their reforms of the medical sector and stand ready to work with them to make the necessary changes for the benefit of patients in China.

This press release is intended for business journalists and analysts/investors. Please note that this release may not have been issued in every market in which GSK operates.